| Nov 12 |
Nuvalent GAAP EPS of $1.28
|
| Nov 12 |
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
|
| Sep 23 |
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
|
| Sep 22 |
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
|
| Sep 19 |
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
|
| Sep 18 |
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
|
| Sep 18 |
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
|
| Sep 17 |
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
|
| Sep 17 |
Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation
|
| Sep 17 |
Company News for Sep 17, 2024
|
